Xinyi Shi

Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.

Jing Sun, Kehui Chen, W. Fang, 2023, Clinical lung cancer.

Circulating tumor DNA–based detection of molecular residual disease as a biomarker for recurrence monitoring predict disease recurrence in patients with ovarian cancer.

Jing Wang, Jing Sun, Dan Zhao, 2023, Journal of Clinical Oncology.